StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
ZRO.CN$0.06+0.00%
Fair $0.06+0.0%

ZRO.CN

Biosenta Inc.

Consumer Defensive / Household & Personal ProductsCanadian Sec

$0.06

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.06Fund rank 30/100 · Data gapFallback financials|
SA 26/D
F-Score: 2/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-566347.00 · quality 76.3/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 41/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

26/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · ZRO.CNLocal privado en este navegador · Biosenta Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

24.9%

↑

Gross Margin

46.8%

↑

Debt/Equity

-0.07

↓
52-Week Range$0
$0$0

TradingView lightweight chart

ZRO.CN price, volumen y niveles de valoración

Último $0.060Periodo -20.0%
Fair value: $0.060

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+1.7%

FCF CAGR

—

FCF margin

-39738.8%

FCF / Net income

0.19x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1211.0 · net income $-2.5M · FCF $-481237.0

2022-FY → 2025-FY

Gross margin

46.8%-16.4% pts

Operating margin

-109577.2%-5599.5% pts

Net margin

-206924.4%-80229.2% pts

FCF margin

-39738.8%+4086.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1211.00$1211.00$1379.00$1042.00$1151.00
Net Income$-2.5M$-2.5M$-2.2M$-6.3M$-1.5M
EBITDA$-1.4M$-1.4M$-1.1M$-6.2M$-1.2M
EPS-0.08-0.08-0.08-0.24-0.07
Gross Margin46.8%46.8%60.6%41.0%63.2%
Operating Margin-109577.2%-109577.2%-80705.4%-138817.1%-103977.8%
Net Margin-206924.4%-206924.4%-161543.0%-604582.9%-126695.1%
Balance Sheet
Debt/Equity-0.07-0.07-0.70-0.72-0.03
Current Ratio0.010.01———
Cash Flow
Free Cash Flow$-481237.00$-481237.00$-779348.00$-566347.00$-504433.00
Returns
ROE24.9%24.9%28.3%80.2%49.9%
Growth & Yield
Revenue Growth-12.2%-12.2%32.3%-9.5%—
EPS Growth0.0%0.0%66.7%-242.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -50.0%

Total return

-50.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.08 → -0.08

Residual

-50.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-50.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.